Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323933 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01323933 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 32 participants.
The verdict
NCT01323933, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Analysis of safety, tolerability, and PK data will provide information that will guide future development of AB0024.
Interventions
- DRUG AB0024
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01323933
The ClinicalTrials.gov registry entry for NCT01323933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AB0024 is the first listed.
NCT01323933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01323933 about?
NCT01323933 is a clinical study titled "First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors". Analysis of safety, tolerability, and PK data will provide information that will guide future development of AB0024.
What is the current status of trial NCT01323933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2010-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01323933?
The interventions under investigation include: AB0024 (DRUG).
Who is sponsoring clinical trial NCT01323933?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.